Clinical Trial

Ivonescimab (AK112) Plus Paclitaxel as Second-line Therapy in Patients With Advanced G/GEJ Cancer

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A Randomized, Controlled, Multi-center Phase II Study of Ivonescimab (AK112) plus Paclitaxel versus Paclitaxel with or without Ramucirumab as second-line therapy in subjects with advanced gastric or gastroesophageal junction（G/GEJ）cancer who failed immunochemotherapy
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-25.
Trial Details
NCT Number NCT06904300
Lead Sponsor Sun Yat-sen University
Conditions Gastric (Cardia, Body) Cancer
Enrollment 110 participants
Start Date 2025-08-15
Primary Completion 2028-04-30 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-06-05